Konrad Stawiski

Radiation oncologist and clinical-translational researcher

Board-certified radiation oncologist and clinical-translational researcher focused on GU/GI radiotherapy, bladder/prostate/rectal cancer care, radiomics, omics biomarkers, radiation-toxicity modeling, and practical medical AI.

Contact and profiles: konrad@konsta.com.pl; Harvard Catalyst; ORCID; PubMed; OpenAlex; Google Scholar; GitHub.

Current roles and focus

- **Visiting Assistant Professor of Radiation Oncology**, Dana-Farber Cancer Institute, Boston, MA, USA.
- **Assistant Professor**, Department of Biostatistics and Translational Medicine, Medical University of Lodz; supervisor of the Artificial Intelligence in Oncology Students' Scientific Group.
- **Radiation Oncologist and Deputy Head of Department of Brachytherapy and General Oncology**, Copernicus Memorial Hospital in Lodz; deputy clinical lead for a 34-bed ward.
- Clinical scope: broad radiotherapy practice with special focus on genitourinary and gastrointestinal cancers, including prostate, bladder, and rectal cancer; SBRT/SRS, brachytherapy, radiochemotherapy, and radioimmunotherapy.

Selected impact

- 97 Google Scholar records; h-index 19; 1,095 citations.
- Partner PI / Polish group lead in the ERA PerMed miRPOC consortium; PI of NCN PRELUDIUM and Radonek-AI projects.
- Co-inventor on circulating microRNA patent families for pancreatic and ovarian cancer; ovarian cancer family publicly described as under commercialization/licensing efforts with Aspira Women's Health.
- Subinvestigator in phase I/II-III oncology trials, including GU, thoracic, head-and-neck, cervical, and advanced solid-tumor studies.
- Editorial Board Member, BMC Cancer; elected member of the ESTRO AI in RT Focus Group.

Selected publications and contributions

- **First author / GU translational oncology:** Stawiski K, Perera-Bel J, Rodriguez-Vida A, Juanpere N, Lee J, Michaud DE, Guerriero JL, Mouw KW, Bamias A, Carvalho FLF, Bellmunt J. **Tumor B-cell infiltration in platinum-treated advanced muscle-invasive urothelial carcinoma.** *Molecular Oncology.* 2026 Jun 1. doi: 10.1002/1878-0261.70276.
- **Bladder cancer / DFCI-Broad collaboration:** Zhou Y, Borcsok J, Adib E, Kamran SC, Neil AJ, Stawiski K, et al. **ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer.** *Science Advances.* 2023;9:eadg2263. doi: 10.1126/sciadv.adg2263.
- **Clinical AI / urologic oncology:** Jobczyk M, Stawiski K, Kaszkowiak M, Rajwa P, Rozanski W, Soria F, et al. **Deep learning-based recalibration of the CUETO and EORTC prediction tools for recurrence and progression of non-muscle-invasive bladder cancer.** *European Urology Oncology.* 2022;5:109-112.
- **Research software / omics modeling:** Stawiski K, Kaszkowiak M, Mikulski D, Hogendorf P, Durczynski A, et al. **OmicSelector: automatic feature selection and deep learning modeling for omic experiments.** *bioRxiv.* 2022. doi: 10.1101/2022.06.01.494299.
- **miRNA biomarker validation:** Stawiski K, Fortner RT, Pestarino L, Umu SU, Kaaks R, Rounge TB, et al. **Validation of miRNA signatures for ovarian cancer earlier detection in the pre-diagnosis setting using machine learning approaches.** *Frontiers in Oncology.* 2024;14:1389066.
- **Patent-linked translational diagnostics:** Elias KM, Fendler W, Stawiski K, Fiascone SJ, Vitonis AF, Berkowitz RS, et al. **Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer.** *eLife.* 2017;6:e28932.
- **Radiation biomarker work:** Nowicka Z, Tomasik B, Kozono D, Stawiski K, Johnson T, Haas-Kogan D, et al. **Serum miRNA-based signature indicates radiation exposure and dose in humans.** *Radiotherapy and Oncology.* 2023;185:109731.
- **Radiation toxicity / dose-volume analytics:** Nowicka Z, Kuna K, Laszczych M, Lazar-Poniatowska M, Sobocki BK, Stawiski K, et al. **Dose-volume metric-based prediction of radiotherapy-induced lymphocyte loss.** *Physics and Imaging in Radiation Oncology.* 2024;30:100593.

Grants, awards, patents

- ERA PerMed miRPOC, Joint Transnational Call 2022: total consortium budget approximately EUR 1,000,000; **Partner PI / Polish group lead** at Medical University of Lodz.
- Prof. Franciszek Walczak NAWA Programme Scholarship, 2025: one of 31 awardees selected from 125 applications; 6-month Dana-Farber / Harvard Medical School fellowship on bladder-preserving treatment strategies in muscle-invasive bladder cancer; institutional report: 94/100.
- NCN PRELUDIUM, 2019-2022: deep neural networks for circulating and intracellular miRNA profiles in pancreatic cancer; **PI**.
- Radonek-AI, 2023-2024: virtual oncology patient assistant, PLN 70,000; **PI**.
- Patent families: circulating microRNA signatures for pancreatic cancer and ovarian cancer.

Clinical trials and research software

- Selected commercial clinical trials as subinvestigator / site clinical team: TALAPRO-2 (mCRPC), KEYNOTE-867 (locally advanced NSCLC chemoradiotherapy + pembrolizumab), KEYNOTE-689 (head-and-neck cancer), CALLA (cervical cancer chemoradiotherapy + durvalumab), NC-6004-009 (advanced solid tumors).
- **RTpipeline:** DICOM RT-to-analysis pipeline for dose-volume, radiomics, and machine-learning workflows.
- **rect-ril:** R/Python pipeline and calculator for severe radiation-induced lymphopenia prediction in rectal cancer; Zenodo DOI 10.5281/zenodo.19595346.
- **Somatic Likelihood Tiering:** tumor-only WES variant triage framework; Zenodo DOI 10.5281/zenodo.19572621.
- **OmicSelector / OmicApp:** R/Docker tools for feature selection and deep-learning modeling in omics experiments.
- **Notatnik Medyczny:** selected digital-health project for structured clinical documentation workflows; public ADK hackathon prototype at github.com/kstawiski/notatnik-adk-slice-public.

Skills

- **Clinical radiation oncology:** GU/GI cancers, bladder-preserving trimodality therapy, prostate and rectal radiotherapy, SBRT/SRS, brachytherapy, radiochemotherapy, radioimmunotherapy, clinical trials.
- **Translational oncology:** radiomics, DICOM RT, DVH analytics, miRNA-seq, RNA-seq, single-cell RNA-seq, WES, biomarkers, radiation toxicity.
- **AI and biostatistics:** prediction modeling, survival analysis, machine learning, deep learning, model validation, reproducible pipelines, clinical decision tools.
- **Research software:** R, Python, Shiny, Docker, GitHub/Zenodo releases, web applications, clinical documentation workflows, OCR/dictation, secure web deployment.

Full CV

Comprehensive CV and full Google Scholar publication archive: English PDF, English DOCX, Polish PDF, Polish DOCX.